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COST-EFFECTIVENESS OF ATOMOXETINE IN
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AND ADOLESCENTS
Iskedjian M1, Maturi B1,Walker JH2, Einarson TR3, Khattak S4,
Carter G4
1PharmIdeas Research and Consulting Inc, Oakville, ON,
Canada; 2Brock University, St. Catharines, ON, Canada;
3University of Toronto,Toronto, ON, Canada; 4The Kids Clinic,
Whitby, ON, Canada
OBJECTIVE: Attention deﬁcit hyperactivity disorder
(ADHD) affects 3%–5% of North Americans <18 years
of age. We conducted a cost-effectiveness (CE) analysis 
of atomoxetine (ATO), a new non-stimulant, against
methylphenidate (MTP) in ADHD. METHODS: Using
TreeAge Data 4.0, we constructed a six-month decision
analytic model. We included preference rates for non-
stimulant over stimulant medication, determined by sur-
veying parents of ADHD children. Efﬁcacy and resource
use data were determined from the literature and expert
opinion. Perspectives considered were: Ontario Ministry
of Health (MoH), which included direct medical costs
(physician visits and drug costs); government (MoH and
Ontario Ministry of Education), which included MoH
costs plus costs of school-based drug administration 
and special education; and society, including the former
costs plus non-pharmacologic interventions such as psy-
chotherapy and over the counter supplements. Prices were
obtained from standard lists and measured in 2002 Cana-
dian dollars. Effectiveness was measured as the number
of symptom free days (SFDs), deﬁned as days of success-
ful treatment. SFDs were assigned for the 2-week period
prior to assessments of successful treatment and for each
successful day remaining in the subsequent cycles. Pref-
erence rates for ATO were varied in a sensitivity analysis
from 57–93% based on 95% conﬁdence intervals of the
normalized ATO rate. RESULTS: In the MoH base-case
analysis for ATO and MTP, respectively, expected costs
were $678 and $162, SFDs were 156 and 98. The incre-
mental cost effectiveness ratio (ICER) was $8.87/addi-
tional SFD for MoH perspective, $8.83/additional SFD
from the government perspective, and $2.00/additional
SFD for societal. In the sensitivity analysis of preference
rates, ICERs ranged from $1.12/SFD (societal) to
$20.34/SFD (MoH perspective). CONCLUSION: We
found a strong preference for non-stimulant therapy,
whose incremental cost was relatively small and quite 
reasonable.
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MEDICAL CARE COSTS FOR TREATING
ATTENTION DEFICIT/HYPERACTIVITY
DISORDER—AN EMPIRICAL STUDY BASED ON
A LARGE ADMINISTRATIVE CLAIM DATA
Sun P, Swindle R
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To examine the medical care costs paid by
commercial health plans for treating attention deﬁcit/
hyperactivity disorder (ADHD) in their health plans.
METHODS: We used a nationally representative claim
data set (Pharmetrics claim database) with 23 million
covered lives and 28 health plans. ADHD patients at dif-
ferent age groups were identiﬁed base on ICD-9 codes.
The mean annual medical care costs for treating ADHD
were calculated for each age group from the medical care
claims that have ADHD ICD-9 codes as principal diag-
nosis. The medical care costs examined in this study
include the costs reimbursed by commercial health plans
for all outpatient services, mental health services, emer-
gency services, and inpatient services claims with ADHD
ICD-9 codes as principal diagnoses, but exclude all 
medication costs. RESULTS: More than 15,000 ADHD
patients were identiﬁed from Pharmetrics data set in year
2000. The mean annual medical care costs for different
age groups were calculated as follows: $221.92 for chil-
dren under age 6; $257 for children age between 6 and
11; $262.71 for teen ages between 12–18; and $202.94
for adults. Using these estimates and assuming 3% preva-
lence of ADHD nationwide, we can extrapolate that, each
year, at least more than $100 millions of medical care
have been consumed for treating ADHD. CONCLU-
SIONS: In addition to medication, ADHD patients in
commercial health plans also consume a signiﬁcant
amount of medical care for treating ADHD. This con-
sumption imposes a ﬁnancial burden to health plans.
Therefore, a new therapeutic approach that can reduce
this burden and has the same therapeutic efﬁcacy should
be encouraged.
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OBJECTIVES: To model the treatment patterns of
ADHD and to assess health economic differences between
standard immediate-release methylphenidate (MPH-IR)
(OD, BID or TID); a new orally administered, once-daily
(OD), long-acting (LA) formulation of methylphenidate
using a unique osmotic release delivery technology
(MPH-OD, LA); and behavioural therapy (BEH) in the
UK. The use of MPH-OD, LA minimizes ﬂuctuations in
peak-trough concentrations improving acute tolerance.
METHODS: Based on a clinical trial by the MTA Coop-
erative Group, a medical decision tree was developed in
MS-Excel, reﬂecting the current treatment strategies and
associated outcomes. The proﬁle for MPH-OD, LA was
determined based on a short-term comparative double-
blind cross-over trial and a 24-month open-label multi-
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center study. The adjusted expected treatment success was
78.4% for MPH-OD, LA compared to 55.6% for MPH-
IR and 33.8% for BEH. Treatment switches or combina-
tions due to adverse events or inefﬁcacy, and a more
intensive follow-up for patients with comorbidities were
accounted for. To identify the resource use associated
with each treatment, 6 centres were asked to provide data
on their management of ADHD in patients between 6 and
16 years old. Data on interventions from parents/care-
givers and teachers were additionally gathered. The ana-
lytical time horizon was one year. RESULTS: Treatment
switches to behavioural treatment occur in 11.8% of
MPH-OD, LA and 24.2% of MPH-IR patients. Starting
treatment with BEH alone resulted in the highest annual
cost (€3453), while starting treatment with MPH-IR
alone (€2138) and MPH-OD, LA alone (2187 Euro) gen-
erated a comparable cost. Probabilistic sensitivity analy-
ses showed that the results were sensitive towards
treatment success and the proportion of patients with
comorbidities. CONCLUSIONS: UK treatment costs 
over one year appear comparable regardless of whether
patients were treated ﬁrst with MPH-OD, LA or MPH-
IR. Treating patients ﬁrst with BEH and then adding stim-
ulant medication if needed resulted in higher overall
annual treatment costs.
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OBJECTIVE: To compare the effect of donepezil versus
placebo on the health and associated costs of caregivers
of patients with mild to moderate Alzheimer’s disease
(AD). METHODS: Two hundred eighty-six patients with
mild to moderate AD were randomized to receive either
donepezil (n = 142) or placebo (n = 144) for 1 year. The
Resource Utilization in Dementia (RUD) questionnaire
was used to obtain information on caregiver healthcare
resource utilization. Costs are reported in Swedish krona
(SEK) and US dollars (USD) using a conversion rate of
8.38. RESULTS: Caregivers in the two treatment groups
were similar with respect to age, marital status and 
the proportion living with the patient. Caregivers of
donepezil-treated patients reported 16 hospitalizations,
involving 69 nights hospital stays compared with 20 hos-
pitalizations, and 122 nights hospitalized in those caring
for the placebo group. Caregiver hospitalization costs
were 432,821 SEK (51,649 USD) for the placebo group
and 254,536 SEK (30,374 USD) for the donepezil group
(p = 0.39). Healthcare professionals were contacted more
often by caregivers of the placebo group than the
donepezil group (811 vs. 613, respectively), with almost
twice as many general practitioner visits (329 vs. 170,
respectively). The average cost of healthcare professional
contact per caregiver was signiﬁcantly higher (p = 0.04)
for caregivers of placebo- versus donepezil-treated
patients. During the study there were 815 reports of med-
ication use by donepezil group caregivers and 1025
reports by placebo group caregivers. A statistically higher
use of antihypertensives (p = 0.015), antipsychotics 
(p = 0.019) and anxiolytics (p = 0.004) was reported in
caregivers of placebo- versus donepezil-treated patients.
CONCLUSIONS: Signiﬁcant global, cognitive and 
functional beneﬁts have previously been reported in
donepezil-treated AD patients from this study. The
current results suggest that these beneﬁts translate into
health beneﬁts for the caregivers of donepezil-treated
patients and a corresponding reduction in caregiver-
associated healthcare costs. Treatment with donepezil
therefore represents an improved strategy for the man-
agement of AD.
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OF DISABILITY
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OBJECTIVES: In considering the impact of Multiple Scle-
rosis (MS) and its treatment, evidence from other chronic
conditions suggests that the economic burden is highly
dependant on level of physical disability. We performed a
comprehensive review of the economic literature to iden-
tify what is known about the relationship between EDSS
categories and cost of MS. METHODS: The review of 
literature was a multi-step process—identiﬁcation of
databases, abstraction of individual articles and creating
evidence tables. We sought cohort studies of patients with
MS that describe costs attributed to each EDSS score, and
utilized speciﬁc inclusion criteria for the selection of 10
studies. RESULTS: Both direct (medical) and indirect
(productivity) costs rise continuously with increasing
EDSS category, this rise is qualitatively exponential. The
rise in indirect costs appears at lower EDSS scores. The
cost of a relapse occurring in any given EDSS category
exceeds that associated with that particular EDSS cate-
gory. Few studies comprehensively assessed the entire
spectrum of the costs associated with MS, and much of
the literature is based on EDSS categories in a coarser
grouping. The costs will depend on the practices that were
current in the population under study, making this a
moving target. CONCLUSION: As more expensive inter-
ventions become available, cost considerations—and
cost-effectiveness analyses in particular—will become
increasingly relevant to decision makers, requiring cost
estimates that explicitly address the impact of progression
of disability. This is a topic of sufﬁcient importance to
deserve more precise and detailed research.
